Anginal chest pain in patients with angiographically normal coronary arteries may be caused by a limited coronary flow response to stress because of abnormal function of the coronary microcirculation (microvascular angina). Studies of forearm arterial function suggested that patients with microvascular angina may have a diffuse disorder of smooth muscle tone. Because dyspnea is common in these patients and seems disproportionate to the severity of myocardial ischemia, we studied air flow (forced expiratory volume in 1 second, or FEV1) in the basal state and after methacholine inhalation to determine whether bronchial smooth muscle is affected in this syndrome. Five of 36 patients with microvascular angina had a basal FEVy of less than 70% of that predicted and did not receive methacholine. Of the remaining 31 patients, 14 (45%) had a more-than-20% reduction in FEV1 after methacholine inhalation (as much as 25 mg/ml), a response significantly greater than that of nine patients with heart disease (0%, p<0.025) and 24 normal volunteers of similar age and gender distribution (13%, p<0.025). Furthermore, the product of the methacholine dose inhaled and the magnitude of decline in FEVY from baseline (methacholine response score) was significantly lower in patients with microvascular angina than in normal volunteers (16±8.6 versus 22.2+3.7, p=0.026). We conclude that airway hyperresponsiveness is frequently demonstrable in patients with microvascular angina; these findings are consistent with our hypothesis that this syndrome may represent a more generalized abnormality of vascular and nonvascular smooth muscle function. (Circulation Approximately 10-30% of patients with anginalike chest pain exhibit no large vessel coronary artery disease at catheterization and have no other myocardial or valvular cause for the pain.1,2 We have found that many of these patients have a dynamic abnormality in coronary flow caused by increased coronary resistance of vessels too small to be imaged angiographically and have applied the term "microvascular angina" to denote this syndrome.3-8
Anginal chest pain in patients with angiographically normal coronary arteries may be caused by a limited coronary flow response to stress because of abnormal function of the coronary microcirculation (microvascular angina). Studies of forearm arterial function suggested that patients with microvascular angina may have a diffuse disorder of smooth muscle tone. Because dyspnea is common in these patients and seems disproportionate to the severity of myocardial ischemia, we studied air flow (forced expiratory volume in 1 second, or FEV1) in the basal state and after methacholine inhalation to determine whether bronchial smooth muscle is affected in this syndrome. Five of 36 patients with microvascular angina had a basal FEVy of less than 70% of that predicted and did not receive methacholine. Of the remaining 31 patients, 14 (45%) had a more-than-20% reduction in FEV1 after methacholine inhalation (as much as 25 mg/ml), a response significantly greater than that of nine patients with heart disease (0%, p<0.025) and 24 normal volunteers of similar age and gender distribution (13%, p<0.025). Furthermore, the product of the methacholine dose inhaled and the magnitude of decline in FEVY from baseline (methacholine response score) was significantly lower in patients with microvascular angina than in normal volunteers (16±8.6 versus 22.2+3.7, p=0.026). We conclude that airway hyperresponsiveness is frequently demonstrable in patients with microvascular angina; these findings are consistent with our hypothesis that this syndrome may represent a more generalized abnormality of vascular and nonvascular smooth muscle function. (Circulation 1990; 82:2011 -2017 ) Approximately 10-30% of patients with anginalike chest pain exhibit no large vessel coronary artery disease at catheterization and have no other myocardial or valvular cause for the pain.1,2 We have found that many of these patients have a dynamic abnormality in coronary flow caused by increased coronary resistance of vessels too small to be imaged angiographically and have applied the term "microvascular angina" to denote this syndrome. [3] [4] [5] [6] [7] [8] Many patients with microvascular angina experience breathlessness during physical or emotional stress. However, the severity of myocardial ischemia during stress appears relatively mild and unlikely to explain this symptom. Of note, studies of forearm arterial function in patients with microvascular angina have suggested an abnormality in forearm vasoconstrictor tone, similar to that in the coronary microcirculation.9 Such a finding raises the suspicion that a diffuse disorder of smooth muscle tone may be present in this syndrome. Hence, the purpose of the present study was to investigate the possibility that a coexisting abnormality of bronchial smooth muscle is present in patients with microvascular angina, leading to increased airway resistance and perhaps associated pulmonary symptoms.
Methods

Study Populations
Three groups underwent spirometry. No patient gave a history of asthma or chronic pulmonary disease.
Chestpain and nonnal coronary arteriograms. Fortythree consecutive patients underwent study of coronary flow response to pacing stress before and following administration of the vasoconstrictor stimulus ergonovine. Thirteen patients were men, and 30 were women (average age, 48 years). Three patients (7%) were active cigarette smokers, and 11 (26%) were exsmokers. Ten (23%) gave a history of drug-related rashes, and two (5%) gave a history of urticaria after angiography. Of the 40 patients who underwent graded exercise treadmill testing (Bruce protocol), seven (18%) had greater than 1 mm horizontal or down-sloping ST segment responses, and four (10%) had bundle branch blocks (three left and one right) during exercise. By radionuclide angiography, 11 (26%) had basal left ventricular ejection fractions between 30% and 45%, and the remainder had basal ejection fractions of more than 45%.
We previously described a coronary vasoconstrictor response to ergonovine, most demonstrable during pacing stress associated with precipitation of the patient's typical chest pain and with metabolic and hemodynamic changes suggestive of ischemia. [3] [4] [5] [6] 8 Because these studies have been performed in patients with angiographically normal appearing coronary arteries and because the coronary vasoconstrictor response to ergonovine involves arterial segments too small to be reliably imaged angiographically, we have termed this syndrome "microvascular angina."8 Because the coronary vasoconstrictor response to ergonovine during pacing stress is one of the hallmarks of this disorder of coronary flow, we prospectively used this coronary hemodynamic response to separate patients with microvascular angina from those in whom no flow abnormality could be demonstrated. This protocol was approved by the institute review board of the National Heart, Lung, and Blood Institute, and informed consent was obtained from all patients.
Great cardiac vein flow measured by thermo-dilution10 was used to estimate coronary flow in the anterior left ventricle and septum, with all measurements made in duplicate and averaged. The protocol for this study has been described by us previously. [3] [4] [5] [6] 8 Briefly, after basal measurements of flow, rapid atrial pacing was performed to a heart rate of 150 beats/ min for 4 minutes in all patients and followed by measurements of great cardiac vein flow and computation of coronary resistance (mean systemic blood pressure divided by flow). After abrupt termination of pacing, ergonovine 0.15 mg was administered intravenously over 2 minutes, with resumption of pacing 2 minutes later at a rate of 150 beats/min for an additional 4 minutes with repeat great cardiac vein flow measurement and coronary resistance computation. Arterial and great cardiac vein blood samples were obtained for oxygen content in the basal state and during pacing. Oxygen extraction was calculated as the arterial minus great cardiac vein oxygen concentration. After pacing, coronary arteriography was immediately performed to exclude epicardial spasm. In all cases, less than 10% diffuse luminal narrowing compared with control arteriograms was noted.
Of the 43 patients with chest pain and angiographically normal coronary arteries, 36 were found to have increased coronary vascular resistance during rapid atrial pacing (heart rate, 150 beats/min) after ergonovine 0.15 mg i.v. (+0.17±0.14 mm Hg . min/ ml); this was associated with an increase in myocardial oxygen extraction (+0.8±1.4 ml O/100 ml) compared with pacing before ergonovine and provocation of their typical chest pains in 34 patients (94%). These 36 patients were defined prospectively as having microvascular angina. As assessed by coronary arteriography, no patient developed more than 10% luminal narrowing of the epicardial coronary arteries in response to ergonovine administration compared with the coronary arteriograms in identical orthogonal views obtained at the start of the study. In contrast, seven patients had an additional decrease in coronary resistance during pacing after ergonovine administration (-0.10±0.9 mm Hg * min/ml); this was associated with a decrease in myocardial oxygen extraction (-0.5±1.1 ml 02J100 ml; p<0.05 versus patients with a coronary vasoconstrictor response to ergonovine) compared with pacing before ergonovine. Furthermore, only two patients (29%) experienced their typical chest pains during pacing (p<O.OOl versus patients with a coronary vasoconstrictor response to ergonovine). These patients were defined as having no coronary flow abnormality.
Heart disease. Nine patients with organic heart disease were studied (seven with coronary artery disease, one with aortic stenosis, and one with hypertrophic cardiomyopathy), all of whom were clinically stable and underwent cardiac catheterization for diagnostic purposes off all medications. Six patients were men, and three were women (average age, 55 years). None was an active smoker, and two (22%) gave a history of drug-related rashes.
Normal volunteers. Twenty-four subjects free of known cardiovascular disease (including hypertension) and on no cardioactive medications were studied. Nine volunteers were men, and 15 were women (average age, 42 years).
Spirometry
All study participants had pulmonary function studies using a Multispiro PC computerized spirometer (Laguna Hills, Calif.) with real-time analysis of air flow. All spirometry was performed with patients off all medications for at least five drug half-lives. The subject was instructed to inhale to functional capacity and then exhale as hard and as rapidly as possible. Baseline spirometry measurements included forced vital capacity (FVC), maximum midexpiratory flow from 25% to 75% of the FVC (MMEF25-75%), and forced expiratory volume in 1 second (FEV1). FEV, was the air flow parameter prospectively used for the methacholine challenge test and represented the average of triplicate measurements. Baseline FEV1 was compared with predicted FEV, for the patient's sex and height through the use of published tables. Methacholine for bron- chial challenge was administered only to patients with baseline FEV1s of more than 70% of predicted normal. Before methacholine administration, FEV1 was obtained after inhalation of nebulized saline to control for inhalation of aerosolized material in the subsequent methacholine challenge test. This FEV1 was used for comparison to subsequent FEV1 determinations after inhalation of methacholine. Methacholine 0.025 mg/ml was inhaled for five tidal volume breaths from a hand-held nebulizer; FEV1 determination followed. If no change or a reduction of less than 20% in the FEV1 was noted, higher concentrations of methacholine (0.25, 2.5, 10.0, and 25.0 mg/ml) could be administered. If the FEVy after any dose of methacholine showed a reduction of more than 20% from control, the study was considered abnormal and no additional methacholine was administered. Thus, all "negative" responders received all five concentrations of methacholine. Cumulative units of methacholine were computed as the sum of the products of five "inhalations" multiplied by each concentration of methacholine administered to that individual. For the concentrations of methacholine used in the present study (0.025, 0.25, 2.5, 10.0, and 25.0 mg/ml), the corresponding cumulative units of methacholine were 0.125, 1.375, 13.9, 63.9, and 188.9.
With the exception of the normal volunteers, spirometric and methacholine inhalation studies were performed and interpreted without knowledge of the patient's diagnosis.
Statistics
Values are given as mean±+1 SD. Comparisons of continuous variables between patients with microvas-cular angina and patients with no coronary flow abnormality were analyzed by two-tailed unpaired t test. Multiple subgroup comparisons were made by one-way analysis of variance, with intergroup comparisons by Scheffe's method. The methacholine response scores were analyzed by the Mann-Whitney U test for nonparametric data. Response rates to methacholine challenge testing were compared by x2 analysis or Fisher's exact test. A probability value of less than 0.05 was considered significant.
Spirometric Studies and Methacholine Challenge Testing
The clinical characteristics and baseline air flow studies of all participants are given in Table 1 . Patients with microvascular angina and patients with heart disease were somewhat older than the volunteers (p<0.025). Baseline FEVy was slightly lower in patients with microvascular angina than in the normal volunteers (p=0.05). However, the percent of predicted FVC, MMEF25-75%, and FEV1 were similar among the subgroups. Five patients with microvascular angina had a baseline FEV1 of less than 70% of that predicted and did not receive methacholine, based on standard guidelines. Three of these five had never been smokers.
All other patients with baseline FEV1 of more than 70% of predicted underwent normal saline inhalation and then methacholine challenge, as described in "Methods." Normal saline inhalation produced minimal and nonsignificant changes in FEV, (Table   2 ). Of the 31 patients with microvascular angina who underwent methacholine challenge, 14 (45%) had a more-than-20% decrease in FEVy from baseline, a response rate significantly greater than that of normal volunteers (three of 24 [13%], p<0.025). Only one of seven patients with no coronary flow abnormality and no patient with heart disease had this response to methacholine (p<0.025 versus patients with microvascular angina). The cumulative dose of methacholine inhaled to produce this response was less for patients with microvascular angina (143+±70 cumulative units) than for the other study participants, although this difference did not achieve statistical significance. Nineteen of 36 patients (53%) with microvascular angina had either abnormal basal or abnormal methacholine-provoked air flow dynamics, a significantly higher prevalence than found in patients with heart disease (none of nine [0%], p<O.OO5) or in normal volunteers (three of 24 [13%], p<0.005) (Figure 1 ). Because two parameters are involved in producing an abnormal airway response to methacholine (magnitude of reduction in FEV1 from baseline and dose 100 of methacholine at which a more-than-20% reduction in FEV, occurred), a methacholine response score was calculated as the product of the highest concentration of methacholine used in an individual patient and the actual FEV1 achieved at that time, as a percent of baseline. The methacholine response score (Table 2 and Figure 2 ) was significantly lower for patients with microvascular angina than for the normal volunteers (p=0.026). Scores for volunteer controls, patients with normal coronary flow responses, and patients with organic heart disease were similar. Although the methacholine response scores for patients with normal coronary flow responses and patients with heart disease were not significantly different from those with microvascular angina, this was due to the small numbers in each group.
Discussion
We previously found that patients with anginal chest pain despite angiographically normal coronary arteries may have myocardial ischemia on the basis of a limited coronary flow reserve.2-8 This conclusion was suggested by the reduced coronary vasodilator response these patients developed to the stress of rapid atrial pacing, pacing after ergonovine, and dipyridamole, a potent coronary arteriolar vasodilator. The mechanism of flow limitation is unknown but may involve abnormalities of small coronary artery function, presumably intramyocardial and prearteriolar in location.7 Recent studies suggest that epicardial coronary arteries may also be dysfunctional.1"'12 The most common coronary hemodynamic feature of this syndrome is heightened sensitivity of the coronary microcirculation to ergonovine, resulting in small artery constriction and increased coronary vascular resistance. The impact on flow is most noticeable during pacing stress, which is usually associated with provocation of the patient's typical chest pain. That this pain is a consequence of myocardial ischemia is suggested by increased extraction of oxygen by the myocardium (a response seen only when flow delivery is limited), decreased lactate consumption, and increased postpacing left ventricular filling pressures. 8 However, the magnitude of ischemia appears to be less severe than in patients with coronary artery disease or hypertrophic cardiomyopathy undergoing similar pacing and exercise protocols in our labora-tory13-'6 as judged by the degree of changes in myocardial lactate2-6,8 and in left ventricular ejection fraction responses to exercise.5 Moreover, the increase in left ventricular end-diastolic pressure observed after pacing is usually modest. Thus, symptoms of breathlessness reported by the majority of our patients have been difficult to explain on a simple Lrt Normal ase Volunteers cardiac basis. Based on our demonstration that patients with microvascular angina exhibit an impaired forearm vasodilator response to forearm ischemia,9 we hypothesized that there might be a diffuse abnormality of smooth muscle tone in this disorder. We therefore decided to determine whether increased bronchoconstrictor tone might also be present in such patients.
The results of the present study of air flow at rest and after methacholine inhalation indicate associated abnormal resting airway resistance in some patients and bronchoconstrictor responses to methacholine in many others. At rest, five of 36 patients with microvascular angina had an FEV1 of less than 70% of predicted. None of these patients was an active smoker, although two did give a remote smoking history (more than 1 year before the study). After inhalation of methacholine, almost one half of the remaining 31 microvascular angina patients demonstrated a more-than-20% reduction in FEV1, a response rate significantly greater than those of normal volunteers and of patients with heart disease. This intriguing association of abnormal bronchoconstrictor response in patients with microvascular angina, who also exhibit reduced forearm vasodilation responses to forearm ischemia, suggests that there may be a diffuse disorder of smooth muscle tone in patients with microvascular angina and that a causal link might exist between abnormally increased smooth muscle tension of vascular (coronary and systemic) and nonvascular (bronchial tree) sites.
The mechanisms responsible for the bronchoconstrictor response to methacholine in patients with microvascular angina are unknown, just as the mechanism of this response in patients with asthma is unclear. However, evidence suggests that patients with spasm of the epicardial coronary arteries may have an endothelial defect, as judged by a coronary constrictor response to acetylcholine.17,18 Moreover, a preliminary report describes an association between variant (Prinzmetal's) angina and a bronchoconstrictor response to methacholine inhalation. 19 Whether alterations in coronary flow reserve might be induced by acetylcholine infusion at the small vessel level in our patients with an abnormal bronchial response to methylcholine is not known at present. Other possible mechanisms include bronchial smooth muscle hypertrophy or hyperplasia, abnormalities in autonomic responsiveness, increase in muscarinic receptor density, and decrease in the release or activity of proposed epithelial relaxant factor in response to smooth muscle constrictor agonists. 20, 21 Another potential precipitating factor for bronchoconstrictor responses in patients with cardiac disease is elevated pulmonary venous pressures. Thus, Cabanes et a122 recently reported methacholineinduced bronchoconstriction in 21 of 23 patients with impaired left ventricular function, 12 of whom gave a history of pulmonary edema. The mechanism of bronchoconstriction in this population probably differs from that of our population, as Cabanes et al's patients were likely to have chronic increases in pulmonary venous pressures. In this regard, the prevalence of abnormal air flow at rest or abnormal methacholine bronchial response in the 11 microvascular angina patients with left ventricular ejection fractions between 30% and 45% (three of 11, or 27%) was actually less than that of patients with ejection fractions of more than 45% (16 of 25, or 64%).
Conclusion
Results from the present study suggest that shortness of breath occurring in patients with chest pain and normal coronary arteries who also have abnormal regulation of coronary flow reserve involving small coronary arteries may be related to abnormal airway hyperresponsiveness. Just as the coronary microcirculation in patients with microvascular angina is excessively responsive to the vasoconstrictor effects of ergonovine, so is their bronchial tree excessively responsive to the smooth muscle constrictor effects of methacholine. Abnormalities in function of other smooth muscle beds in patients with microvascular angina, including the forearm circulation9 and the esophagus,23 suggest that this syndrome, at least in some patients, may represent a generalized abnormality of smooth muscle function. Determination of the mechanisms of this disorder and the pathophysiological linkage among these various smooth muscle beds necessitate further study.
